Financial Performance - The company's revenue for Q3 2024 was ¥385,505,275.46, a decrease of 9.18% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥61,587,550.89, representing a decline of 229.50% year-over-year[2]. - The net profit after deducting non-recurring gains and losses was -¥68,821,451.60, down 242.34% from the previous year[2]. - Total profit for the year-to-date was ¥115,592,000.00, a decrease of 66.87% compared to the previous year[5]. - Net profit for Q3 2024 was CNY 108,985,799.47, down 66.00% from CNY 320,617,148.08 in the same period last year[14]. - Total comprehensive income for Q3 2024 was CNY 111.32 million, a decrease of 66% compared to CNY 327.83 million in Q3 2023[17]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,156,138,045.60, an increase of 10.20% compared to the end of the previous year[2]. - Current liabilities totaled CNY 935,180,788.14, significantly higher than CNY 568,624,898.28, indicating a rise of 64.43%[13]. - Non-current liabilities increased to CNY 100,829,314.67 from CNY 56,838,545.27, reflecting an increase of 77.43%[13]. - Total current assets increased to ¥2,890,010,108.38 from ¥2,625,395,995.52, reflecting an increase of about 10.08%[11]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥31,906,075.99, a significant decrease of 86.77% year-over-year[2]. - Net cash flow from operating activities for Q3 2024 was CNY 31.91 million, a significant decrease of 86.7% compared to CNY 241.15 million in Q3 2023[17]. - Cash inflow from investment activities was CNY 781.78 million in Q3 2024, compared to CNY 472.52 million in Q3 2023, showing an increase of 65.4%[17]. - Cash outflow from investment activities reached CNY 1.21 billion in Q3 2024, significantly higher than CNY 304.06 million in Q3 2023, indicating a rise of 297.5%[17]. - Net cash flow from financing activities was CNY 160.11 million in Q3 2024, a turnaround from a net outflow of CNY 129.27 million in Q3 2023[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,324, with the top ten shareholders holding a combined 74.12% of shares[7]. - The largest shareholder, Chen Zhiqiang, holds 22.12% of shares, amounting to 95,725,200 shares, with 7,330,000 shares pledged[7]. - The top ten shareholders include various institutional investors, with the largest institutional shareholder being China Bank with 1.68% of shares[9]. - The total number of preferred shareholders at the end of the reporting period is not applicable, indicating no preferred shares were issued[10]. Research and Development - Research and development expenses for the year-to-date amounted to ¥33,830.78 million, an increase of 28.33% compared to the same period last year[5]. - Research and development expenses rose to CNY 338,307,834.78, compared to CNY 263,619,138.72, marking an increase of 28.31%[14]. Market Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to recover from the current decline in revenue[14]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[18]. Inventory and Financial Assets - Inventory has risen significantly to ¥776,308,431.54 from ¥531,476,404.12, indicating an increase of approximately 46.06%[11]. - The company reported a 471.47% increase in trading financial assets, reaching ¥293,680,400.00 at the end of the reporting period[5]. - The company has a total of 293,680,436.11 in trading financial assets, a substantial increase from ¥51,390,000.00 at the beginning of the period[11].
开立医疗(300633) - 2024 Q3 - 季度财报